

10 March 2026

Convatec Group Plc
("Convatec" or "the Company")
Annual Report and Accounts 2025

The Company's Annual Report and Accounts for the year ended 31 December 2025 (the "2025 Annual Report") has been published on the Company's website at www.convatecgroup.com.

For those shareholders who have elected to receive paper communications, copies of the 2025 Annual Report are due to be posted to shareholders shortly.

In accordance with UK Listing Rule 6.4.1 of the UK Financial Conduct Authority ("FCA"), a copy of the 2025 Annual Report will be submitted to the FCA and will be available for public inspection at the National Storage Mechanism, <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>.

This announcement is made in accordance with DTR 6.3.5R(1A).

Enquiries

James Kerton, Company Secretary
Email: cosec@convatec.com

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

Classification: 1.1 Annual financial and audit reports

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over 2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit <http://www.convatecgroup.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSBGDGXUSBDGLG